Purpose: To test the effect of conditional survival on 36-months’ cancer-specific mortality (CSM)-free survival in non-metastatic muscle-invasive adenocarcinoma of the bladder (ACB). Materials and methods: Within the Surveillance, Epidemiology, and End Results database (2000–2018), ACB patients treated with radical cystectomy (RC) were identified. Multivariable competing risks regression (CRR) analyses assessed the independent predictor status of organ-confined (OC, T2N0M0) vs non-organ-confined stage (NOC, T3-4N0M0 or TanyN1-3M0) on CSM. Conditional 36-months’ CSM-free survival estimates were computed based on event-free intervals of 12, 24, 36, 48 and 60 months after RC, according to stage. Results: Of 475 ACB patients, 132 (28%) harbored OC vs 343 (72%) harbored NOC stage. In multivariable CRR models, NOC vs OC stage independently predicted lower CSM (hazard ratio 3.55; 95% CI 2.66, 5.83; p < 0.001). Conversely, neither chemotherapy nor radiotherapy were independently associated with CSM. In OC stage, 36-months’ CSM-free survival rate was 84% at baseline. Provided event-free intervals of 12, 24, 36, 48 and 60 months, conditional 36-months’ CSM-free survival estimates were 84, 87, 87, 89 and 89%. In NOC stage, 36-months’ CSM-free survival rate was 47% at baseline. Provided event-free intervals of 12, 24, 36, 48 and 60 months, conditional 36-months’ CSM-free survival estimates were 51, 62, 69, 78 and 85%. Conclusions: Conditional survival estimates provide better insight into survival of patients with longer event-free follow-up. In consequence, conditional survival estimates might be highly valuable for individual patient counselling.
Conditional survival for non-metastatic muscle-invasive adenocarcinoma of the urinary bladder after radical cystectomy / Tappero, S.; Cano Garcia, C.; Incesu, R. -B.; Piccinelli, M. L.; Barletta, F.; Morra, S.; Scheipner, L.; Tian, Z.; Saad, F.; Shariat, S. F.; Borghesi, M.; Terrone, C.; Karakiewicz, P. I.. - In: SURGICAL ONCOLOGY. - ISSN 0960-7404. - 48:(2023). [10.1016/j.suronc.2023.101947]
Conditional survival for non-metastatic muscle-invasive adenocarcinoma of the urinary bladder after radical cystectomy
Barletta F.;Morra S.;
2023
Abstract
Purpose: To test the effect of conditional survival on 36-months’ cancer-specific mortality (CSM)-free survival in non-metastatic muscle-invasive adenocarcinoma of the bladder (ACB). Materials and methods: Within the Surveillance, Epidemiology, and End Results database (2000–2018), ACB patients treated with radical cystectomy (RC) were identified. Multivariable competing risks regression (CRR) analyses assessed the independent predictor status of organ-confined (OC, T2N0M0) vs non-organ-confined stage (NOC, T3-4N0M0 or TanyN1-3M0) on CSM. Conditional 36-months’ CSM-free survival estimates were computed based on event-free intervals of 12, 24, 36, 48 and 60 months after RC, according to stage. Results: Of 475 ACB patients, 132 (28%) harbored OC vs 343 (72%) harbored NOC stage. In multivariable CRR models, NOC vs OC stage independently predicted lower CSM (hazard ratio 3.55; 95% CI 2.66, 5.83; p < 0.001). Conversely, neither chemotherapy nor radiotherapy were independently associated with CSM. In OC stage, 36-months’ CSM-free survival rate was 84% at baseline. Provided event-free intervals of 12, 24, 36, 48 and 60 months, conditional 36-months’ CSM-free survival estimates were 84, 87, 87, 89 and 89%. In NOC stage, 36-months’ CSM-free survival rate was 47% at baseline. Provided event-free intervals of 12, 24, 36, 48 and 60 months, conditional 36-months’ CSM-free survival estimates were 51, 62, 69, 78 and 85%. Conclusions: Conditional survival estimates provide better insight into survival of patients with longer event-free follow-up. In consequence, conditional survival estimates might be highly valuable for individual patient counselling.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
